Pancreatic Cancer Early Detection Consortium (PRECEDE)
Categories (click each to see list of all clinical trials associated with that category): GI (ONC)
Current Status: Open
Phase: N/A (Cancer Prevention)
Principal Investigator: Klute, Kelsey
Contact Information:
Suzanne Wessling
suzanne.wessling@unmc.edu
Summary
The main objective of the PRECEDE Consortium is to build a shared resource to drive research in critical areas necessary for early detection and prevention of PDAC.
Data and samples collected for PRECEDE will allow the consortium to address a variety of topic areas including but not limited to:
1. Developing and/or validating early detection biomarker tests
2. Improving risk modeling and risk prediction for PDAC
3. Identifying and studying novel high penetrance germline pathogenic variants causing PDAC risk
4. Designing and implementing enhanced communication tools about PDAC risk, genetic testing, and early detection for patients and health care providers
5. Studying modifying factors for PDAC risk including common genetic variants and modifiable/lifestyle factors
6. Developing and/or validating PDAC prevention strategies for high-risk individuals